SPARKLERStudy

Are you or a loved one prescribed FILSPARI®? Help us learn more

If you've recently started FILSPARI® (sparsentan), or are about to begin treatment, you might be eligible to participate in a voluntary clinical research study.

Travere Therapeutics is conducting an important observational study for people with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) who are taking this medicine.

Why Your Participation Matters

Observational studies are an important way to collect everyday health information from patients living with IgAN and FSGS. By joining, you can help:

- Improve the understanding of FILSPARI's safety
- Support research into any potential drug-induced liver injury
- Contribute to better care for future IgAN and FSGS patients

What to Expect

- No extra doctor visits, tests, or procedures
- No changes to your treatment plan
- Participation lasts about 2 years
  - We will reach out to your doctor every three months for a brief health update and may follow up with you if they cannot be reached or if we need more information
- After you enroll, you may receive compensation if we need to contact you directly

You May Qualify If You:

- Are 8 years or older
- Plan to begin FILSPARI treatment or have started FILSPARI treatment within the past 12 months
- Are willing and able to sign an Informed Consent Form (ICF) or have parent/legal guardian consent

For more information:

If you are interested in participating or would like more information, please contact a study representative at 1-866-974-3979.
Hours of Operation: M - F 9:00am - 5:00pm ET

You can also visit our website at www.FILSPARI-registry.com or scan the QR code for additional details.

v1.0_09Jun2026